PMID- 34589428
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230921
IS  - 2234-943X (Print)
IS  - 2234-943X (Electronic)
IS  - 2234-943X (Linking)
VI  - 11
DP  - 2021
TI  - B4GALNT2 Gene Promotes Proliferation, and Invasiveness and Migration Abilities of 
      Model Triple Negative Breast Cancer (TNBC) Cells by Interacting With HLA-B 
      Protein.
PG  - 722828
LID - 10.3389/fonc.2021.722828 [doi]
LID - 722828
AB  - B4GALNT2 gene encodes the enzyme beta1,4-N-acetylgalactosaminyltransferase 2 that 
      biosynthesizes the histo-blood group antigen Sd(a), which is expressed on the 
      surface of erythrocytes and in body secretions. Analysis of The Cancer Genome 
      Atlas (TCGA) database revealed that this gene was highly expressed in breast 
      cancer tissues in comparison with adjacent healthy ones. In-vitro 
      lentivirus-assisted B4GALNT2 gene knockdown experiments in model triple negative 
      breast cancer (TNBC) cell lines (HCC1937 and MDA-MB-231) showed inhibition in 
      cell proliferation, decrease in cell viability, promotion of cell apoptosis and 
      inhibitions in cell migration and invasiveness abilities in comparison with empty 
      lentivirus transfectant controls. Also, in cell cycle tests, the number of cells 
      in the G1 phase increased, in the S phase decreased and did not change in the 
      G2/M phase (indicative of the presence of a block in the G1 phase). In-vivo tumor 
      formation experiments in mice revealed that knockdown of the B4GALNT2 gene in 
      MDA-MB-231 cells inhibited their proliferation. Using co-immunoprecipitation 
      (Co-IP) mass spectroscopy-assisted analysis, it was found that HLA-B protein [a 
      product of the human leukocyte antigen (HLA) class I gene] interacts with 
      B4GALNT2 protein. In-vitro overexpression of HLA-B in B4GALNT2-knocked down 
      MDA-MB-231 cell lines significantly recovered the cell proliferation, viability 
      and migration ability of B4GALNT2 gene. These indicate that HLA-B is one of the 
      interaction proteins in the downstream pathway of the B4GALNT2 gene.
CI  - Copyright (c) 2021 Yu, Zhu, Cui, Du, Zhang, Ma and Guo.
FAU - Yu, Pu
AU  - Yu P
AD  - Department of Oncology, The First Affiliated Hospital of Zhengzhou University, 
      Zhengzhou, China.
FAU - Zhu, Lili
AU  - Zhu L
AD  - Department of Oncology, The First Affiliated Hospital of Zhengzhou University, 
      Zhengzhou, China.
FAU - Cui, Kang
AU  - Cui K
AD  - Department of Oncology, The First Affiliated Hospital of Zhengzhou University, 
      Zhengzhou, China.
FAU - Du, Yabing
AU  - Du Y
AD  - Department of Oncology, The First Affiliated Hospital of Zhengzhou University, 
      Zhengzhou, China.
FAU - Zhang, Chaojie
AU  - Zhang C
AD  - Nephrology Research Center, The First Affiliated Hospital of Zhengzhou 
      University, Zhengzhou, China.
FAU - Ma, Wang
AU  - Ma W
AD  - Department of Oncology, The First Affiliated Hospital of Zhengzhou University, 
      Zhengzhou, China.
FAU - Guo, Jia
AU  - Guo J
AD  - Nephrology Research Center, The First Affiliated Hospital of Zhengzhou 
      University, Zhengzhou, China.
LA  - eng
PT  - Journal Article
DEP - 20210913
PL  - Switzerland
TA  - Front Oncol
JT  - Frontiers in oncology
JID - 101568867
PMC - PMC8473878
OTO - NOTNLM
OT  - B4GALNT2
OT  - HLA-B protein
OT  - invasiveness
OT  - migration
OT  - triple negative breast cancer
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2021/10/01 06:00
MHDA- 2021/10/01 06:01
PMCR- 2021/01/01
CRDT- 2021/09/30 07:16
PHST- 2021/06/09 00:00 [received]
PHST- 2021/08/16 00:00 [accepted]
PHST- 2021/09/30 07:16 [entrez]
PHST- 2021/10/01 06:00 [pubmed]
PHST- 2021/10/01 06:01 [medline]
PHST- 2021/01/01 00:00 [pmc-release]
AID - 10.3389/fonc.2021.722828 [doi]
PST - epublish
SO  - Front Oncol. 2021 Sep 13;11:722828. doi: 10.3389/fonc.2021.722828. eCollection 
      2021.